S Korea's Mirae Asset Venture co-leads $18m funding in KAHR Medical

South Korea’s Mirae Asset Venture Investment has co-led an $18 million investment in KAHR Medical Ltd., an Israeli biopharmaceutical company that claims to be developing a novel drug platform based on bi-functional, immunotherapeutic fusion proteins, according to an announcement.